STIVARGA in Gastrointestinal Stromal Tumors (GIST) ~ 3/23/23! Coming up!

STIVARGA in gastrointestinal stromal tumors (GIST)

Join your colleagues for a discussion on important topics in order to:

• How STIVARGA works as an oral inhibitor of multiple kinases

• Strategies for managing certain treatment-emergent adverse events (TEAEs), including dose modifications and temporary or permanent discontinuations

• Bayer’s patient support programs, including financial and nursing support for patients

Indications

STIVARGA is indicated for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR therapy.

STIVARGA is indicated for the treatment of patients with locally advanced, unresectable, or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.

STIVARGA is indicated for hepatocellular carcinoma (HCC) patients who have been previously treated with sorafenib.

Date: 3/23/2023

Time: 6:00 PM Eastern Time (Panama)

Venue: Davio's

Address: 75 Arlington Street Boston Massachusetts, 2116

Bayer Presenter:

Julie Melia, DNP

RSVP to janice.jeziorski@bayer.com